Kyntra Bio, Inc. (KYNB) Stock Score, Valuation & Financial Research
Kyntra Bio, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 49/100.
Quick answer for KYNB
Kyntra Bio, Inc. currently has a Wall Street Score of 49/100. The stored market price is $7.97. Its financial score is 25/100. Its valuation score is 100/100. These figures are a research snapshot, not a buy or sell recommendation.
What Kyntra Bio, Inc. does
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
KYNB financial snapshot
- Wall Street Score:
- 49/100
- Current price:
- $7.97
- Market capitalization:
- $32.3M
- Revenue:
- $7.4M
- Net income:
- $163.6M
- Free cash flow:
- $-4.8M
- Cash:
- $37.0M
- Total debt:
- $19.2M
- EPS:
- 45.37
- P/E ratio:
- 0.2x
- Financial score:
- 25/100
- Valuation score:
- 100/100
- Revenue score:
- 53/100
What stands out
- Reported year-over-year revenue growth is +0.2%.
- Free cash flow is $-4.8M, showing cash burn in the current stored period.
- The balance sheet shows $37.0M of cash versus $19.2M of total debt, leaving more cash than debt.
- The current research record carries a severe debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 100/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research KYNB
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.